B-control	0	10	Anesthesia
O	11	14	and
B-intervention	15	26	Circulating
I-intervention	27	32	Tumor
I-intervention	33	38	Cells
O	39	41	in
O	42	49	Primary
O	50	56	Breast
O	57	63	Cancer
O	64	72	Patients
O	72	73	:
O	74	75	A
O	76	86	Randomized
O	87	97	Controlled
O	98	103	Trial
O	103	104	.

O	105	108	The
O	109	115	effect
O	116	118	of
O	119	129	anesthetic
O	130	135	drugs
O	136	138	on
O	139	145	cancer
O	146	154	outcomes
O	155	162	remains
O	163	170	unclear
O	170	171	.

O	172	176	This
O	177	182	trial
O	183	188	aimed
O	189	191	to
O	192	198	assess
O	199	212	postoperative
O	213	224	circulating
O	225	230	tumor
O	231	235	cell
O	236	242	counts
O	242	243	-
O	243	245	an
O	246	257	independent
O	258	268	prognostic
O	269	275	factor
O	276	279	for
O	280	286	breast
O	287	293	cancer
O	293	294	-
O	294	296	to
O	297	306	determine
O	307	310	how
O	311	321	anesthesia
O	322	325	may
O	326	336	indirectly
O	337	343	affect
O	344	353	prognosis
O	353	354	.

O	355	357	It
O	358	361	was
O	362	374	hypothesized
O	375	379	that
O	380	388	patients
O	389	398	receiving
O	399	410	sevoflurane
O	411	416	would
O	417	421	have
O	422	428	higher
O	429	442	postoperative
O	443	448	tumor
O	449	453	cell
O	454	460	counts
O	460	461	.

O	462	465	The
O	466	474	parallel
O	474	475	,
O	476	486	randomized
O	487	497	controlled
O	498	503	trial
O	504	507	was
O	508	517	conducted
O	518	520	in
O	521	524	two
O	525	532	centers
O	533	535	in
B-location	536	547	Switzerland
O	547	548	.

O	549	557	Patients
O	558	562	aged
B-age	563	565	18
I-age	566	568	to
I-age	569	571	85
I-age	572	574	yr
B-eligibility	575	582	without
I-eligibility	583	593	metastases
I-eligibility	594	597	and
I-eligibility	598	607	scheduled
I-eligibility	608	611	for
I-eligibility	612	619	primary
I-eligibility	620	626	breast
I-eligibility	627	633	cancer
I-eligibility	634	641	surgery
O	642	646	were
O	647	655	eligible
O	655	656	.

O	657	660	The
O	661	669	patients
O	670	674	were
O	675	683	randomly
O	684	692	assigned
O	693	695	to
O	696	702	either
O	703	714	sevoflurane
O	715	717	or
O	718	726	propofol
O	727	737	anesthesia
O	737	738	.

O	739	742	The
O	743	751	patients
O	752	755	and
O	756	763	outcome
O	764	773	assessors
O	774	778	were
O	779	786	blinded
O	786	787	.

O	788	791	The
O	792	799	primary
O	800	807	outcome
O	808	811	was
B-outcome-Measure	812	823	circulating
I-outcome-Measure	824	829	tumor
I-outcome-Measure	830	834	cell
I-outcome-Measure	835	841	counts
I-outcome-Measure	842	846	over
I-outcome-Measure	847	851	time
O	851	852	,
O	853	861	assessed
O	862	864	at
O	865	870	three
O	871	875	time
O	876	882	points
O	883	898	postoperatively
O	899	900	(
O	900	901	0
O	901	902	,
O	903	905	48
O	905	906	,
O	907	910	and
O	911	913	72
O	914	915	h
O	915	916	)
O	917	919	by
O	920	923	the
O	924	934	CellSearch
O	935	940	assay
O	940	941	.

O	942	951	Secondary
O	952	960	outcomes
O	961	969	included
B-outcome-Measure	970	977	maximal
I-outcome-Measure	978	989	circulating
I-outcome-Measure	990	995	tumor
I-outcome-Measure	996	1001	cells
I-outcome-Measure	1002	1007	value
O	1007	1008	,
B-outcome-Measure	1009	1019	positivity
O	1020	1021	(
O	1021	1027	cutoff
O	1027	1028	:
O	1029	1031	at
O	1032	1037	least
O	1038	1039	1
O	1040	1043	and
O	1044	1046	at
O	1047	1052	least
O	1053	1054	5
O	1055	1060	tumor
O	1061	1066	cells
O	1066	1067	/
O	1067	1068	7
O	1068	1069	.
O	1069	1070	5
O	1071	1073	ml
O	1074	1079	blood
O	1079	1080	)
O	1080	1081	,
O	1082	1085	and
O	1086	1089	the
B-outcome-Measure	1090	1101	association
I-outcome-Measure	1102	1109	between
I-outcome-Measure	1110	1117	natural
I-outcome-Measure	1118	1124	killer
I-outcome-Measure	1125	1129	cell
I-outcome-Measure	1130	1138	activity
I-outcome-Measure	1139	1142	and
I-outcome-Measure	1143	1148	tumor
I-outcome-Measure	1149	1153	cell
I-outcome-Measure	1154	1160	counts
O	1160	1161	.

O	1162	1166	This
O	1167	1172	trial
O	1173	1176	was
O	1177	1187	registered
O	1188	1192	with
O	1193	1207	ClinicalTrials
O	1207	1208	.
O	1208	1211	gov
O	1212	1213	(
O	1213	1224	NCT02005770
O	1224	1225	)
O	1225	1226	.

O	1227	1234	Between
O	1235	1240	March
O	1241	1245	2014
O	1246	1249	and
O	1250	1255	April
O	1256	1260	2018
O	1260	1261	,
B-total-participants	1262	1265	210
O	1266	1278	participants
O	1279	1283	were
O	1284	1292	enrolled
O	1292	1293	,
O	1294	1302	assigned
O	1303	1305	to
O	1306	1317	sevoflurane
O	1318	1319	(
O	1319	1320	n
O	1321	1322	=
B-intervention-participants	1323	1326	107
O	1326	1327	)
O	1328	1330	or
O	1331	1339	propofol
O	1340	1341	(
O	1341	1342	n
O	1343	1344	=
B-control-participants	1345	1348	103
O	1348	1349	)
O	1350	1360	anesthesia
O	1360	1361	,
O	1362	1365	and
O	1366	1376	eventually
O	1377	1385	included
O	1386	1388	in
O	1389	1392	the
O	1393	1401	analysis
O	1401	1402	.

O	1403	1413	Anesthesia
O	1414	1418	type
O	1419	1422	did
O	1423	1426	not
O	1427	1433	affect
B-outcome	1434	1445	circulating
I-outcome	1446	1451	tumor
I-outcome	1452	1456	cell
I-outcome	1457	1463	counts
I-outcome	1464	1468	over
I-outcome	1469	1473	time
O	1474	1475	(
O	1475	1481	median
O	1482	1493	circulating
O	1494	1499	tumor
O	1500	1504	cell
O	1505	1510	count
O	1511	1512	[
O	1512	1525	interquartile
O	1526	1531	range
O	1531	1532	]
O	1532	1533	;
O	1534	1537	for
O	1538	1546	propofol
O	1546	1547	:
O	1548	1549	1
O	1550	1551	[
O	1551	1552	0
O	1553	1555	to
O	1556	1557	4
O	1557	1558	]
B-outcome	1559	1561	at
I-outcome	1562	1563	0
I-outcome	1564	1565	h
O	1565	1566	,
O	1567	1568	1
O	1569	1570	[
O	1570	1571	0
O	1572	1574	to
O	1575	1576	2
O	1576	1577	]
B-outcome	1578	1580	at
I-outcome	1581	1583	48
I-outcome	1584	1585	h
O	1585	1586	,
O	1587	1590	and
O	1591	1592	0
O	1593	1594	[
O	1594	1595	0
O	1596	1598	to
O	1599	1600	1
O	1600	1601	]
B-outcome	1602	1604	at
I-outcome	1605	1607	72
I-outcome	1608	1609	h
O	1609	1610	;
O	1611	1614	and
O	1615	1618	for
O	1619	1630	sevoflurane
O	1630	1631	:
O	1632	1633	1
O	1634	1635	[
O	1635	1636	0
O	1637	1639	to
O	1640	1641	4
O	1641	1642	]
B-outcome	1643	1645	at
I-outcome	1646	1647	0
I-outcome	1648	1649	h
O	1649	1650	,
O	1651	1652	0
O	1653	1654	[
O	1654	1655	0
O	1656	1658	to
O	1659	1660	2
O	1660	1661	]
B-outcome	1662	1664	at
I-outcome	1665	1667	48
I-outcome	1668	1669	h
O	1669	1670	,
O	1671	1674	and
O	1675	1676	1
O	1677	1678	[
O	1678	1679	0
O	1680	1682	to
O	1683	1684	2
O	1684	1685	]
B-outcome	1686	1688	at
I-outcome	1689	1691	72
I-outcome	1692	1693	h
O	1693	1694	;
O	1695	1699	rate
O	1700	1705	ratio
O	1705	1706	,
O	1707	1708	1
O	1708	1709	.
O	1709	1711	27
O	1712	1713	[
O	1713	1715	95
O	1715	1716	%
O	1717	1719	CI
O	1719	1720	,
O	1721	1722	0
O	1722	1723	.
O	1723	1725	95
O	1726	1728	to
O	1729	1730	1
O	1730	1731	.
O	1731	1733	71
O	1733	1734	]
O	1734	1735	;
O	1736	1737	P
O	1738	1739	=
O	1740	1741	0
O	1741	1742	.
O	1742	1745	103
O	1745	1746	)
O	1747	1749	or
O	1750	1760	positivity
O	1760	1761	.

O	1762	1764	In
O	1765	1768	one
O	1769	1778	secondary
O	1779	1787	analysis
O	1787	1788	,
O	1789	1803	administrating
O	1804	1815	sevoflurane
O	1816	1819	led
O	1820	1822	to
O	1823	1824	a
O	1825	1836	significant
O	1837	1845	increase
O	1846	1848	in
B-outcome	1849	1856	maximal
I-outcome	1857	1862	tumor
I-outcome	1863	1867	cell
I-outcome	1868	1874	counts
O	1875	1890	postoperatively
O	1890	1891	.

O	1892	1897	There
O	1898	1901	was
O	1902	1904	no
O	1905	1916	association
O	1917	1924	between
O	1925	1932	natural
O	1933	1939	killer
O	1940	1944	cell
O	1945	1953	activity
O	1954	1957	and
O	1958	1969	circulating
O	1970	1975	tumor
O	1976	1980	cell
O	1981	1987	counts
O	1987	1988	.

O	1989	1991	In
O	1992	1996	this
O	1997	2007	randomized
O	2008	2018	controlled
O	2019	2024	trial
O	2025	2038	investigating
O	2039	2042	the
O	2043	2049	effect
O	2050	2052	of
O	2053	2063	anesthesia
O	2064	2066	on
O	2067	2069	an
O	2070	2081	independent
O	2082	2092	prognostic
O	2093	2099	factor
O	2100	2103	for
O	2104	2110	breast
O	2111	2117	cancer
O	2117	2118	,
O	2119	2124	there
O	2125	2128	was
O	2129	2131	no
O	2132	2142	difference
O	2143	2150	between
O	2151	2162	sevoflurane
O	2163	2166	and
O	2167	2175	propofol
O	2176	2180	with
O	2181	2188	respect
O	2189	2191	to
O	2192	2203	circulating
O	2204	2209	tumor
O	2210	2214	cell
O	2215	2221	counts
O	2222	2226	over
O	2227	2231	time
O	2231	2232	.
